Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.74 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.48 |
| ▸ | PRKDC | P78527 | 4/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18041774 | 1.00 | MAPK14 (0.74) | MAPK14PIK3CAPRKDCIDO1MEN1 | |
| SCHEMBL18042095 | 0.99 | MAPK14 (0.73) | MAPK14PIK3CAPRKDCIDO1MEN1 | |
| SCHEMBL18042049 | 0.98 | MAPK14 (0.74) | MAPK14PIK3CAPRKDCIDO1MEN1 | |
| SCHEMBL18041483 | 0.96 | MAPK14 (0.77) | MAPK14PIK3CAPRKDCIDO1MEN1 | |
| SCHEMBL18042007 | 0.88 | MAPK14 (0.75) | MAPK14IDO1 | |
| SCHEMBL18041653 | 0.86 | MAPK14 (0.75) | MAPK14IDO1 | |
| SCHEMBL18041853 | 0.86 | MAPK14 (1.00) | MAPK14IDO1 | |
| SCHEMBL18041834 | 0.82 | MAPK14 (0.80) | MAPK14IDO1MAPTKMT2A | |
| SCHEMBL18041632 | 0.81 | MAPK14 (0.78) | MAPK14IDO1MAPTKMT2A | |
| SCHEMBL5836210 | 0.81 | MAPK14 (0.78) | MAPK14IDO1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056918-B2 | Benzimidazole anti-inflammatory compounds | PFIZER, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1370557-B1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | PFIZER PROD INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1370557-A1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | Pfizer Products Inc. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002072576-A1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | MAPK1, JAK1, CNKSR1 | MAPK14 22/4885PIK3CA 1672/4885PRKDC 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.